<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03067675</url>
  </required_header>
  <id_info>
    <org_study_id>Triton RDB</org_study_id>
    <nct_id>NCT03067675</nct_id>
  </id_info>
  <brief_title>Triton Reference Database</brief_title>
  <official_title>Topcon DRI OCT Triton Reference Database Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Topcon Medical Systems, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Topcon Medical Systems, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to collect OCT measurement data on normal healthy eyes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to collect OCT measurement data on normal healthy eyes in
      order to determine the reference limits for Topcon DRI OCT Triton based on the percentile
      points for 1%, 5%, 95%, and 99%.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Anticipated">September 30, 2017</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Retinal Thickness</measure>
    <time_frame>1 Minute</time_frame>
    <description>The thickness of the macula layer</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Healthy Eyes</condition>
  <arm_group>
    <arm_group_label>Subjects Presenting With Normal Eyes</arm_group_label>
    <description>Subjects with no known ocular diseases will be scanned on the Topcon DRI OCT Triton (plus) device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Topcon DRI OCT Triton (plus)</intervention_name>
    <description>OCT Machine used for diagnostic purposes</description>
    <arm_group_label>Subjects Presenting With Normal Eyes</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The subject population will consist of subjects without eye disease.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Subjects 18 years of age or older on the date of informed consent

          2. Subjects able to understand the written informed consent and willing to participate as
             evidenced by signing the informed consent

          3. Subjects presenting at the site with normal eyes bilaterally (cataracts are
             acceptable)

          4. IOP â‰¤ 21 mmHg bilaterally

          5. BCVA 20/40 or better bilaterally

        Exclusion Criteria

          1. Subjects unable to tolerate ophthalmic imaging

          2. Subjects with ocular media not sufficiently clear to obtain acceptable OCT images

          3. HFA visual field (24-2 Sita Standard, white on white) result unreliable (based on
             manufacturer's recommendation), defined as fixation losses &gt; 20% or false positives &gt;
             33%, or false negatives &gt; 33%

          4. Visual field defects consistent with glaucomatous optic nerve damage based on at least
             one of the following two findings:

               1. On pattern deviation (PD), there exists a cluster of 3 or more points in an
                  expected location of the visual field depressed below the 5% level, at least 1 of
                  which is depressed below the 1% level;

               2. Glaucoma hemi-field test &quot;outside normal limits.&quot;

          5. Narrow angle

          6. History of leukemia, dementia or multiple sclerosis

          7. Concomitant use of hydroxychloroquine and chloroquine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Riesman, MS</last_name>
    <role>Study Chair</role>
    <affiliation>Topcon Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southern California College of Optometry</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accessoreyes Optometry</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois College of Optometry</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fischer Laser Eye Center</name>
      <address>
        <city>Willmar</city>
        <state>Minnesota</state>
        <zip>56201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York VA</name>
      <address>
        <city>Jamaica</city>
        <state>New York</state>
        <zip>11425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stat University of New York College of Optometry</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2017</study_first_submitted>
  <study_first_submitted_qc>February 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2017</study_first_posted>
  <last_update_submitted>August 3, 2017</last_update_submitted>
  <last_update_submitted_qc>August 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>no known ocular pathology</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

